Molnupiravir D7
| Product Name | Molnupiravir D7 |
|---|---|
| Alternate Names | Molnupiravir Stable Isotopes, Stable Isotopes of Molnupiravir |
| CAT No. | CS-T-94052 |
| CAS No. | 2492423-29-5 (Unlabeld) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 336.35 g/mol |
| Mol. For. | C₁₃H₁₂D₇N₃O₇ |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Molnupiravir |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Molnupiravir D7 is a deuterated form of Molnupiravir, a potential antiviral drug developed by Merck. Molnupiravir D7 contains seven deuterium atoms, which provide improved pharmacokinetic properties, such as increased half-life and reduced clearance.
Molnupiravir D7 is a prodrug of the active metabolite, N-hydroxycytidine, which acts as a nucleoside analog and inhibits viral replication by causing mutations in the viral RNA. This mechanism of action makes Molnupiravir D7 a promising candidate for the treatment of viral infections, such as COVID-19, influenza, and respiratory syncytial virus.
In preclinical studies, Molnupiravir D7 has shown potent antiviral activity against SARS-CoV-2, the virus responsible for COVID-19. In a clinical trial, Molnupiravir D7 was found to significantly reduce viral load in COVID-19 patients within five days of treatment.
The safety and efficacy of Molnupiravir D7 are still being evaluated in clinical trials, but early results are promising. If approved, Molnupiravir D7 could provide a much-needed treatment option for COVID-19 and other viral infections.
Get an Instant Quote
Related Compounds
Molnupiravir 13C15N2 |